The grant covers multiple areas of research and early development of product candidates in NOMADS’ R&D pipeline, including, but not limited to, generation of different chimeric novel bacteriocins as well as in vitro and in vivo preclinical studies of the molecules. The grant provides NOMADS with access to external contract research organizations.

“We are very pleased that NOMADS was able to secure a grant in a highly competitive bidding process“, said Prof. Jurijus Gleba, Nomad’s CEO. “It will add additional EUR 0.85 million to NOMADS’ research budget over the next two years. The total amount of secured support from the Government in previous and current grants to NOMADS now reached over EUR 2.2 million. We are grateful to Lithuanian government authorities for their strategic efforts to support high-tech, in particular biotech start-ups and young companies. High quality of the research at NOMADS is reflected in the registration of their first product as GRAS in USA, filing several important patents and publications in the best peer reviewed journals. NOMADS and its parent company Nomad are among few companies developing antibacterials of entirely new classes, and we intend to aggressively develop our products and bring them to the market promptly through partnerships with strategic partners.”

About NOMADS UAB

Nomads UAB is a biotechnology company developing new non-antibiotic antibacterials, including bacteriocins and phage endolysins, to be used as pharmaceuticals, food additives and medical devices. Current emphasis of NOMADS is control of multi-drug and pan-drug resistant Gram-negative bacteria such as Klebsiella and Pseudomonas.
Contact info: linas.kaleda@nomadsbio.lt